ArticleJournal of medicinal chemistry2026
Structure-Activity Relationship of Cycling Molecular Assemblies for Golgi Targeting and Disruption.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Targeting the Golgi apparatus with small molecules remains challenging because of limited binding targets and poor selectivity in cells. We recently introduced cycling molecular assemblies (CyMAs), which use a palmitoylation/depalmitoylation enzyme switch to kinetically trap supramolecular nanostructures at the Golgi, but the molecular features governing their activity were unclear. Here, we report a structure-activity relationship (SAR) study of CyMA by systematically varying the peptide backbone, thioester warhead, and N-terminal capping group. Analysis of Golgi localization, trapping kinetics, critical aggregation concentration (CAC), and cytotoxicity revealed that the self-assembling ability is the primary determinant of CyMA activity. The d-Phe-d-Phe backbone exhibits optimal assembly and enables efficient Golgi accumulation at nanomolar concentrations. Warhead and N-terminal modifications further tune trapping kinetics and disrupt potency. Together, these results define design principles for CyMA and establish enzyme-driven self-assembly as a general, modular strategy for developing drugs for Golgi and organelle targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.